1-10 of 10
pembrolizumab
Close
Sort by
Journal Articles

Low-density PD-1 expression on resting human natural killer cells is functional and upregulated after transplantation

Zachary Davis, Martin Felices, Todd Lenvik, Sujan Badal, Joshua T. Walker, Peter Hinderlie, James L. Riley, Daniel A. Vallera, Bruce R. Blazar, Jeffrey S. Miller
Journal: Blood Advances
Blood Adv (2021) 5 (4): 1069–1080.
https://doi.org/10.1182/bloodadvances.2019001110
Published: 2021
Includes: Supplemental data
Journal Articles

Pembrolizumab in mycosis fungoides with PD-L1 structural variants

Clinical Trials & Observations
Sara Beygi, Sebastian Fernandez-Pol, George Duran, Erica B. Wang, Henning Stehr, James L. Zehnder, Nirasha Ramchurren, Steven P. Fling, Martin A. Cheever, Wen-Kai Weng, Youn H. Kim, Michael S. Khodadoust
Journal: Blood Advances
Blood Adv (2021) 5 (3): 771–774.
https://doi.org/10.1182/bloodadvances.2020002371
Published: 2021
Journal Articles

Phase 2 study of pembrolizumab for measurable residual disease in adults with acute lymphoblastic leukemia

Clinical Trials & Observations
Ryan D. Cassaday, Kelsey-Leigh A. Garcia, Jonathan R. Fromm, Mary-Elizabeth M. Percival, Cameron J. Turtle, Paul T. Nghiem, Phillip A. Stevenson, Elihu H. Estey
Journal: Blood Advances
Blood Adv (2020) 4 (14): 3239–3245.
https://doi.org/10.1182/bloodadvances.2020002403
Published: 2020
Includes: Supplemental data
Journal Articles

KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure

Clinical Trials & Observations
Philippe Armand, John Kuruvilla, Jean-Marie Michot, Vincent Ribrag, Pier Luigi Zinzani, Ying Zhu, Patricia Marinello, Akash Nahar, Craig H. Moskowitz
Journal: Blood Advances
Blood Adv (2020) 4 (12): 2617–2622.
https://doi.org/10.1182/bloodadvances.2019001367
Published: 2020
Includes: Supplemental data
Journal Articles

PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation

Matthew J. Frigault, Philippe Armand, Robert A. Redd, Erin Jeter, Reid W. Merryman, Kimberly C. Coleman, Alex F. Herrera, Parastoo Dahi, Yago Nieto, Ann S. LaCasce, David C. Fisher, Samuel Y. Ng, Oreife O. Odejide, Arnold S. Freedman, Austin I. Kim, Jennifer L. Crombie, Caron A. Jacobson, Eric D. Jacobsen, Jeffrey L. Wong, Jad Bsat, Sanjay S. Patel, Jerome Ritz, Scott J. Rodig, Margaret A. Shipp, Yi-Bin Chen, Robin M. Joyce
Journal: Blood Advances
Blood Adv (2020) 4 (1): 122–126.
https://doi.org/10.1182/bloodadvances.2019000784
Published: 2020
Includes: Supplemental data
Journal Articles

Manasanch EE, Han G, Mathur R, et al. A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis. Blood Adv. 2019;3(15):2400-2408.

Journal: Blood Advances
Blood Adv (2019) 3 (18): 2712.
https://doi.org/10.1182/bloodadvances.2019000881
Published: 2019
Journal Articles

A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis

Elisabet E. Manasanch, Guangchun Han, Rohit Mathur, Yun Qing, Zheng Zhang, Hans Lee, Donna M. Weber, Behrang Amini, Zuzana Berkova, Karina Eterovic, Shaojun Zhang, Jianhua Zhang, Xingzhi Song, Xizeng Mao, Margaret Morgan, Lei Feng, Veera Baladandayuthapani, Andrew Futreal, Linghua Wang, Sattva S. Neelapu, Robert Z. Orlowski
Journal: Blood Advances
Blood Adv (2019) 3 (15): 2400–2408.
https://doi.org/10.1182/bloodadvances.2019000300
Published: 2019
Includes: Supplemental data
Journal Articles

Long-term remissions after stopping pembrolizumab for relapsed or refractory multiple myeloma

Clinical Trials & Observations
Ashraf Z. Badros, Ning Ma, Aaron P. Rapoport, Emily Lederer, Alexander M. Lesokhin
Journal: Blood Advances
Blood Adv (2019) 3 (11): 1658–1660.
https://doi.org/10.1182/bloodadvances.2019000191
Published: 2019
Journal Articles

Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide

Laura K. Schoch, Kenneth R. Cooke, Nina D. Wagner-Johnston, Ivana Gojo, Lode J. Swinnen, Philip Imus, Ephraim J. Fuchs, Mark Levis, Richard F. Ambinder, Richard J. Jones, Douglas E. Gladstone
Journal: Blood Advances
Blood Adv (2018) 2 (17): 2226–2229.
https://doi.org/10.1182/bloodadvances.2018019208
Published: 2018
Journal Articles

Clinical, molecular, and immunological responses to pembrolizumab treatment of synchronous melanoma and acute myeloid leukemia

Clinical Trials & Observations
Anne Sophie Kubasch, Rebekka Wehner, Serena Bazzurri, Antje Tunger, Sebastian Stasik, Marlene Garzarolli, Jörn Meinel, Gustavo Baretton, Friedegund Meier, Christian Thiede, Marc Schmitz, Uwe Platzbecker
Journal: Blood Advances
Blood Adv (2018) 2 (11): 1187–1190.
https://doi.org/10.1182/bloodadvances.2017014811
Published: 2018
Includes: Supplemental data